dalbavancin
Sign in to saveDalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU (both by AbbVie) among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA).
Research
886 papers- Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.Clinical pharmacokinetics · 2022
- Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.International journal of antimicrobial agents · 2023
- Dalbavancin.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021
- A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis.Infection · 2025
- Dalbavancin.Drugs · 2008
via PubMed
Article
10 sectionsContents
- Medical uses
- Contraindications
- Side effects
- Drug interactions
- Pregnancy and lactation
- Production and composition
- Mechanism of action
- Metabolism
- History
- References
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 385028149 | image = Dalbavancin_B0.svg | image_class = skin-invert-image | alt =
| pronounce = | tradename = Dalvance, Xydalba, others | Drugs.com = | MedlinePlus = a614036 | DailyMedID = Dalbavancin | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = Intravenous | class = | ATC_prefix = J01 | ATC_suffix = XA04 | ATC_supplemental =